BioSpace News Archive

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the fourth quarter and year ended December 31, 2020.

Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease, announced financial results for the fourth quarter and year ended December 31, 2020 and provided an update on key initiatives.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the fourth quarter and full year of 2020.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe, Turkey, Middle East and Africa.

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the fourth quarter and full year ending December 31, 2020, on Thursday, March 4, 2021, after the close of the US market.

Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced its participation in the 41st Annual Cowen Healthcare Conference, which takes place March 1-4, 2021.

For the fourth quarter ended December 31, 2020, revenue increased 6.2% to $1,460.5 million, compared to $1,374.6 million for the same quarter, prior year.

Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually March 9 – 10, 2021.